Versor Investments LP Takes Position in Phreesia, Inc. (NYSE:PHR)

Versor Investments LP bought a new stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,441 shares of the company's stock, valued at approximately $694,000. Versor Investments LP owned approximately 0.05% of Phreesia at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PHR. Trust Point Inc. increased its holdings in shares of Phreesia by 3.5% during the third quarter. Trust Point Inc. now owns 17,887 shares of the company's stock valued at $408,000 after acquiring an additional 607 shares in the last quarter. Ensign Peak Advisors Inc increased its holdings in shares of Phreesia by 3.2% in the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company's stock valued at $477,000 after purchasing an additional 700 shares during the period. ProShare Advisors LLC raised its stake in shares of Phreesia by 8.6% in the first quarter. ProShare Advisors LLC now owns 9,522 shares of the company's stock worth $228,000 after purchasing an additional 751 shares during the last quarter. Rhumbline Advisers boosted its position in Phreesia by 1.0% in the second quarter. Rhumbline Advisers now owns 82,136 shares of the company's stock valued at $1,741,000 after buying an additional 853 shares during the last quarter. Finally, Swiss National Bank increased its holdings in Phreesia by 1.0% in the 1st quarter. Swiss National Bank now owns 104,300 shares of the company's stock worth $2,496,000 after buying an additional 1,000 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Balaji Gandhi sold 3,502 shares of Phreesia stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $81,421.50. Following the completion of the sale, the chief financial officer now directly owns 98,578 shares of the company's stock, valued at approximately $2,291,938.50. The trade was a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Allison C. Hoffman sold 1,212 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total value of $25,488.36. Following the completion of the transaction, the general counsel now directly owns 119,791 shares in the company, valued at $2,519,204.73. This trade represents a 1.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,107 shares of company stock worth $1,035,226 over the last 90 days. Corporate insiders own 5.80% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on PHR shares. DA Davidson reiterated a "buy" rating and issued a $32.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. Truist Financial upped their price target on Phreesia from $29.00 to $31.00 and gave the company a "buy" rating in a research report on Friday, September 6th. Robert W. Baird raised their target price on Phreesia from $31.00 to $34.00 and gave the stock an "outperform" rating in a research note on Friday, September 6th. JMP Securities restated a "market outperform" rating and set a $30.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday, September 5th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Phreesia currently has a consensus rating of "Moderate Buy" and an average price target of $29.42.

Phreesia Trading Down 6.1 %

Shares of NYSE PHR traded down $1.37 during trading on Thursday, reaching $20.99. The stock had a trading volume of 478,434 shares, compared to its average volume of 447,305. The business's 50-day moving average price is $21.49 and its 200-day moving average price is $22.04. Phreesia, Inc. has a fifty-two week low of $14.55 and a fifty-two week high of $29.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The company has a market cap of $1.21 billion, a P/E ratio of -12.09 and a beta of 0.94.

Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.06. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The company had revenue of $102.12 million for the quarter, compared to analyst estimates of $101.76 million. On average, equities research analysts predict that Phreesia, Inc. will post -1.23 EPS for the current fiscal year.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.